TAKING KESIMPTA

Treat Relapsing MS at Home or On the Go, Once a Month.*

Someone from your health care team will give you guidance on how to take KESIMPTA® for the first time. After that:

You can take it yourself using the prefilled auto-injector pen.
There are no premedications required† and no 1st dose observation needed.
When ready, it's less than 1 minute a month* to take KESIMPTA.

MS, multiple sclerosis.

*Typical administration time when ready to inject. Once monthly after 3 weekly starter doses.

†Only limited benefit of premedication with corticosteroids, antihistamines, or acetaminophen was seen in RMS clinical studies.

HOW THE KESIMPTA SENSOREADY® PEN WORKS

quotes quotes The idea of giving myself a shot, and needles in general, seemed pretty scary. But once I held the Sensoready® auto-injector pen, I knew I could do it. quotes quotes

– SARAH Q.

Sarah Q. has taken KESIMPTA and has been compensated for her time.

quotes The idea of giving myself a shot, and needles in general, seemed pretty scary. But once I held the Sensoready® auto-injector pen, I knew I could do it. quotes

– SARAH Q.

Sarah Q. has taken KESIMPTA and has been compensated for her time.

MEET THE KESIMPTA SENSOREADY® PEN

The Kesimpta (ofatumumab) Sensoready Pen has no visible needle and a helpful, green indicator. 2 clicks.

Ensure the progress indicator fills the window and stops moving before removing the KESIMPTA Sensoready® Pen. Full Instructions for Use.
^‡KESIMPTA Sensoready® Pen comes with a staked needle of 29-gauge. Pediatric needles average between 23-gauge and 25-gauge.
^§KESIMPTA Sensoready® Pens must be refrigerated at 2 °C to 8 °C (36 °F to 46 °F). Keep in original carton to protect from light until use. If necessary, they may be stored at room temperature below 30 °C (86 °F) for up to 7 days and returned to refrigerator, to be used within 7 days. If not used within those 7 days, discard the medicine.

Ensure the progress indicator fills the window and stops moving before removing the KESIMPTA Sensoready® Pen. Full Instructions for Use.

^‡KESIMPTA Sensoready® Pen comes with a staked needle of 29-gauge. Pediatric needles average between 23-gauge and 25-gauge.
^§KESIMPTA Sensoready® Pens must be refrigerated at 2 °C to 8 °C (36 °F to 46 °F). Keep in original carton to protect from light until use. If necessary, they may be stored at room temperature below 30 °C (86 °F) for up to 7 days and returned to refrigerator, to be used within 7 days. If not used within those 7 days, discard the medicine.

quotes Since starting KESIMPTA, I take it at home and go. Unlike an infusion, I don't have to take time off from work, arrange for family care, or manage transportation to get to my treatment. quotes

– MAGGIE S.

Maggie S. has taken KESIMPTA and has been compensated for her time.

quotes Since starting KESIMPTA, I take it at home and go. Unlike an infusion, I don't have to take time off from work, arrange for family care, or manage transportation to get to my treatment. quotes

– MAGGIE S.

Maggie S. has taken KESIMPTA and has been compensated for her time.

WHAT PEOPLE ARE SAYING

In a real-world survey,^|| we asked people taking KESIMPTA® to tell us what they thought about the KESIMPTA
Sensoready® Pen. Here's what they had to say:

Patients who take KESIMPTA
found the pen easy to use^||:

^||Real-world survey of 105 US patients (aged ≥18) who have been diagnosed with RMS for more than 1 year and who self-administered KESIMPTA using the Sensoready® Pen within the previous 12 months. Participants were asked 30 questions. Ratings were measured on a scale of 1-5, with higher scores indicating positive responses. 89.5% of patients scored a 4 or 5 on characteristics of overall ease of use and ease of monthly dosing schedule. Questionnaire has not been validated.

HERE'S HOW TO GET STARTED ON KESIMPTA DOSING

You'll give yourself 1 dose per week for the first 3 weeks, and then you'll skip a week.
After that, you can move on to 1 dose per month.

Three starter doses, kesimpta dosing chart

Pick a day and start with 1 dose a week for the first 3 weeks. Skip the 4th week.

First monthly dose, kesimpta dosing chart

Take your first monthly maintenance dose on the 5th week.

Maintenance doses, kesimpta dosing chart

Continue taking KESIMPTA once a month.

TRACKING TIP

To keep it simple, try to take KESIMPTA on the same date every month.

EXAMPLE: If your first monthly dose is on April 15, take your next dose on May 15.

TRACKING TIP

To keep it simple, try to take KESIMPTA on the same date every month.

EXAMPLE: If your first monthly dose is on April 15, take your next dose on May 15.

KESIMPTA & Other B-cell Treatments

With the KESIMPTA auto-injector pen, you can treat your RMS at home in less than one minute a month, when
ready. Other B-cell treatments are administered by infusion.

KESIMPTA is administered once a month subcutaneously after 3 weekly starter doses.
Ocrevus and Briumvi are dosed twice yearly via infusion.

^¶Typical administration time when ready to inject. Someone from your health care team will give you guidance on how to take KESIMPTA for the first time.

This is not a complete list of all the available treatments for RMS. The comparison pertains only to differences in dosing and administration and should not be considered a comparison of efficacy or safety. Please see each product's respective Prescribing Information for additional information including indication, dosing, and safety. Trademarks are the property of their respective owners.

^¶Typical administration time when ready to inject. Someone from your health care team will give you guidance on how to take KESIMPTA for the first time.

GET MORE TIPS FOR TAKING KESIMPTA

Someone from your health care team
will give you guidance on how to use the
KESIMPTA Sensoready® Pen for the
first time. If you're nervous, you can receive your first dose at your doctor's office.

Learn how you can pay
as little as $0 co-pay.^#

GET STARTED WITH ALONGSIDE KESIMPTA

Take a look at commonly asked questions.

GET SOME ANSWERS

IMPORTANT SAFETY INFORMATION

Who should not take KESIMPTA?

Do NOT take KESIMPTA if you:

have an active hepatitis B virus (HBV) infection.
have had an allergic reaction to ofatumumab or life-threatening

INDICATION

What is KESIMPTA (ofatumumab) injection?

KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS)

KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple

IMPORTANT SAFETY INFORMATION & INDICATION

INDICATION

What is KESIMPTA (ofatumumab) injection?

KESIMPTA is a prescription medicine used to treat adults with relapsing forms of multiple sclerosis (MS) including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease.

It is not known if KESIMPTA is safe or effective in children.

IMPORTANT SAFETY INFORMATION

Who should not take KESIMPTA?

Do NOT take KESIMPTA if you:

have an active hepatitis B virus (HBV) infection.
have had an allergic reaction to ofatumumab or life-threatening injection-related reaction to KESIMPTA.

What is the most important information I should know about KESIMPTA?

KESIMPTA can cause serious side effects such as:

Infections. Serious infections, which can be life-threatening or cause death, can happen during treatment with KESIMPTA. If you have an active infection, your health care provider (HCP) should delay your treatment with KESIMPTA until your infection is gone. KESIMPTA taken before or after other medicines that weaken the immune system may increase your risk of getting infections. Tell your HCP right away if you have any infections or get any symptoms including painful and frequent urination, nasal congestion, runny nose, sore throat, fever, chills, cough, or body aches.

INDICATION

What is KESIMPTA (ofatumumab) injection?

It is not known if KESIMPTA is safe or effective in children.

HBV reactivation. If you have ever had HBV infection, it may become active again during or after treatment with KESIMPTA (reactivation). If this happens, it may cause serious liver problems including liver failure or death. Before starting KESIMPTA, your HCP will do a blood test to check for HBV. They will also continue to monitor you during and after treatment with KESIMPTA for HBV. Tell your HCP right away if you get worsening tiredness or yellowing of your skin or the white part of your eyes.
Progressive Multifocal Leukoencephalopathy (PML). PML may happen with KESIMPTA. PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. Tell your HCP right away if you have any new or worsening neurologic signs or symptoms. These may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory, which may lead to confusion and personality changes.
Weakened immune system. KESIMPTA taken before or after other medicines that weaken the immune system could increase your risk of getting infections.

Before you take KESIMPTA, tell your HCP about all your medical conditions, including if you:

Have or think you have an infection including HBV or PML.
Have ever taken, currently take, or plan to take medicines that affect your immune system. These medicines could increase your risk of getting an infection.
Have had a recent vaccination or are scheduled to receive any vaccinations.
- You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with KESIMPTA. You should not receive 'live' or 'live-attenuated' vaccines while you are being treated with KESIMPTA and until your HCP tells you that your immune system is no longer weakened.
- Whenever possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with KESIMPTA.
- Talk to your HCP about vaccinations for your baby if you used KESIMPTA during your pregnancy.
Are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if KESIMPTA will harm your unborn baby. Females who can become pregnant should use birth control (contraception) during treatment with KESIMPTA and for 6 months after your last treatment. Talk with your HCP about what birth control method is right for you during this time.
Are breastfeeding or plan to breastfeed. It is not known if KESIMPTA passes into your breast milk. Talk to your HCP about the best way to feed your baby if you take KESIMPTA.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How should I use KESIMPTA?

See the detailed Instructions for Use that comes with KESIMPTA for information about how to prepare and inject a dose of KESIMPTA and how to properly throw away (dispose of) used KESIMPTA Sensoready pens or prefilled syringes.

Use KESIMPTA exactly as your HCP tells you to use it.
Your HCP will show you how to prepare and inject KESIMPTA the right way before you use it for the first time.
Do not inject into areas where the skin is tender, bruised, red, scaly or hard. Avoid areas with moles, scars, or stretch marks.

KESIMPTA may cause serious side effects including:

Injection-related reactions. Injection-related reactions are a common side effect of KESIMPTA. Injecting KESIMPTA can cause injection-related reactions that can happen within 24 hours (1 day) following the first injections and with later injections. There are two kinds of reactions:
- at or near the injection site: redness of the skin, swelling, itching, and pain. Talk to your HCP if you have any of these signs and symptoms.
- that may happen when certain substances are released in your body: fever, headache, pain in the muscles, chills, tiredness, rash, hives, trouble breathing, swelling of the face, eyelids, lips, mouth, tongue and throat, and feeling faint, or chest tightness. Contact your HCP right away if you experience any of these signs and symptoms, especially if they become worse or you have new severe signs of reactions after subsequent injections. It could be a sign of an allergic reaction, which can be serious.
Low immunoglobulins. KESIMPTA may cause a decrease in some types of antibodies. Your HCP will do blood tests to check your blood immunoglobulin levels.

The most common side effects of KESIMPTA include:

Upper respiratory tract infection, with symptoms such as sore throat and runny nose, and headache.
Headache.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information including Medication Guide.

KESIMPTA, the KESIMPTA logo, and SENSOREADY are registered trademarks of Novartis AG.

ALONGSIDE and the ALONGSIDE logo are trademarks of Novartis AG.

AUBAGIO is a registered trademark of Genzyme, a Sanofi company.

Please see each product's respective PI for additional information including indication, dosing, and safety.

Treat Relapsing MS at Home or On the Go, Once a Month.*

HOW THE KESIMPTA SENSOREADY® PEN WORKS

MEET THE KESIMPTA SENSOREADY® PEN

WHAT PEOPLE ARE SAYING

HERE'S HOW TO GET STARTED ON KESIMPTA DOSING

KESIMPTA & Other B-cell Treatments

KESIMPTA is administered once a month subcutaneously after 3 weekly starter doses. Ocrevus and Briumvi are dosed twice yearly via infusion.

GET MORE TIPS FOR TAKING KESIMPTA

Watch our Quick Tips video for tips and instructions on how to administer.

Get complete details about how to take KESIMPTA.

Learn about support and virtual training available through Alongside™ KESIMPTA.

KESIMPTA is administered once a month subcutaneously after 3 weekly starter doses.
Ocrevus and Briumvi are dosed twice yearly via infusion.